Cancer stem cells, which fuel the growth of fatal tumours, can be knocked out by a one-two combination of antibiotics and Vitamin C, researchers at the University of Salford in the UK said.
The antibiotic, doxycycline, followed by doses of ascorbic acid (Vitamin C), were surprisingly effective in killing the cancer stem cells under laboratory conditions.
The researchers said their method offers a new explanation for how to prevent cancer cells from becoming treatment-resistant and how combinations therapies can be developed to overcome drug resistance.
As doxycycline and Vitamin C are both relatively non- toxic, this could dramatically reduce the possible side- effects of anti-cancer therapy, researchers said.
"Certain cancer cells - which we call metabolically flexible - are able to switch their fuel source," said Professor Michael Lisanti from University of Salford.
The new combination approach prevents cancer cells from changing their diet (metabolically inflexible), and effectively starves them, by preventing them from using any other available types of bio-fuels.
The team added doxycycline in ever increasing doses over a three-month period, to induce metabolic inflexibility.
The result was to leave the cancer cells alive, but severely attenuated and depleted, so that they would be much more susceptible to starvation, by a second metabolic "punch".
First, the researchers inhibited the tumour cell mitochondria, by restricting the cancer cells only to glucose as a fuel source; then, they took away their glucose, effectively starving the cancer cells to death.
The team also identified eight other drugs that could be used as a "second-punch" after the antibiotic regime, including berberine (a natural product) - and a number of cheap non-toxic approved drugs.
"This is further evidence that Vitamin C and other non- toxic compounds may have a role to play in the fight against cancer," Lisanti said.
"Our results indicate it is a promising agent for clinical trials, and a as an add-on to more conventional therapies, to prevent tumour recurrence, further disease progression and metastasis," he said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
